Any current/future new fundraising through debt or equity?

The company has completed a preferential allotment, expecting to raise around ₹189 crores through QIP (Qualified Institutional Placement). The preferential allotment was approved in the General Board meeting and Annual General Meeting at the end of September. Filing with authorities has been done in the first week of October, and approval is expected by November with 25% payment to be received within 15 days post-approval. The funds raised will be primarily used for expanding backward integration in technicals and intermediates (₹80-90 crores) and the balance for working capital (₹110-12

Any current/future capex/capital investment/strategic investment?

Planned CapEx of around ₹80-90 crores funded through preferential allotment, focused on backward integration for technicals and intermediates. CapEx execution expected in multiple phases, with completion within 6 to 9 months (~2-3 quarters). The CapEx involves brownfield expansion, with plant trials and stabilization anticipated by Q1-Q2 FY26. Future growth planning for additional CapEx will be considered after current project completion. Development of a production facility for herbicides and patented formulations for international markets is in progress (timeline 1-3 years depending on regis

Future growth expectations in sales/revenue/volumes?

The company targets revenues of ₹450 crore per quarter in upcoming quarters, achievable through specialty molecule sales rather than generics. Management confidently expects over 100% volume growth in Q3 and Q4 to achieve these revenue targets. FY25 topline guidance indicates at least 15-16% growth, aiming to cross ₹2,100 crore in revenue. FY26 growth is expected to be around 20% driven by new patented product launches and market expansion. New product launches each year (2-3) include patented herbicides, fungicides, and insecticides to sustain growth. Southern market penetration and

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects at least 15-16% top-line revenue growth for FY25, with revenues anticipated to exceed ₹2,000 crores, potentially crossing ₹2,100 crores. For FY26, management projects around 20% growth in top line. EBITDA margins are expected to improve, supported by focus on patented molecules and branded products, with recent gross margin expansion from 26% to 34% YoY. B2C business, with higher gross margins (~40-45%) compared to B2B (20-25%), is set to increase its revenue share, improving overall profitability. PAT margins have improved to around 13% in Q2 FY25, with expectation

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention a current or expected order book or pending orders in quantitative terms. However, Management highlighted a strong demand outlook, particularly for the upcoming Rabi season, expecting good numbers in Q3 and Q4. There is confidence in achieving more than 2100 crores revenue in FY25, driven by specialty patented products and new herbicides like "Shot Down," indicating a healthy sales pipeline. Inventory levels remain high (873 crores as of September) but largely liquidated, and SAP implementation has improved visibility on channel inventory and liquidat

IN US

Sale is live|00:00:00left today

Best Agrolife LtdQ3 FY24Fertilizers & Agrochemicals

Best Agrolife Ltd Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹15.5P/E: 28.8Market Cap: ₹697 CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

Yes

Order

N/A

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→The company targets revenues of ₹450 crore per quarter in upcoming quarters, achievable through specialty molecule sales rather than generics.
→Management confidently expects over 100% volume growth in Q3 and Q4 to achieve these revenue targets.
→FY25 topline guidance indicates at least 15-16% growth, aiming to cross ₹2,100 crore in revenue.
→FY26 growth is expected to be around 20% driven by new patented product launches and market expansion.
→New product launches each year (2-3) include patented herbicides, fungicides, and insecticides to sustain growth.
→Southern market penetration and an improved understanding of regional dynamics bolster confidence in growth.
→International business development is progressing, but registrations may take 1-6 years; focus is on patented molecules to compete globally, especially against China.
→Transition towards a B2C brand model (Sudarshan and Best Agro) by FY27 aims to increase margins and overall sales.

Margin guidance

Category 1

→The company expects at least 15-16% top-line revenue growth for FY25, with revenues anticipated to exceed ₹2,000 crores, potentially crossing ₹2,100 crores.
→For FY26, management projects around 20% growth in top line.
→EBITDA margins are expected to improve, supported by focus on patented molecules and branded products, with recent gross margin expansion from 26% to 34% YoY.
→B2C business, with higher gross margins (~40-45%) compared to B2B (20-25%), is set to increase its revenue share, improving overall profitability.
→PAT margins have improved to around 13% in Q2 FY25, with expectations of continued profit growth aligned with top-line expansion.
→New product launches (patented herbicide "Shot Down" and innovative insecticides) in Q3 and Q4 FY25 are expected to drive further revenue and profit growth.
→Improvement in return provisions and inventory management through SAP implementation may positively impact earnings in upcoming quarters.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→The company has completed a preferential allotment, expecting to raise around ₹189 crores through QIP (Qualified Institutional Placement).
→The preferential allotment was approved in the General Board meeting and Annual General Meeting at the end of September.
→Filing with authorities has been done in the first week of October, and approval is expected by November with 25% payment to be received within 15 days post-approval.
→The funds raised will be primarily used for expanding backward integration in technicals and intermediates (₹80-90 crores) and the balance for working capital (₹110-120 crores).
→No mention of new debt fundraising was made; the company reported an improved debt-to-equity ratio from 0.90 to 0.59 as of September 2024.

Order book

→The transcript does not explicitly mention a current or expected order book or pending orders in quantitative terms.
→However, Management highlighted a strong demand outlook, particularly for the upcoming Rabi season, expecting good numbers in Q3 and Q4.
→There is confidence in achieving more than 2100 crores revenue in FY25, driven by specialty patented products and new herbicides like "Shot Down," indicating a healthy sales pipeline.
→Inventory levels remain high (873 crores as of September) but largely liquidated, and SAP implementation has improved visibility on channel inventory and liquidation.
→The company is focusing on expanding in southern markets and international registrations, which could contribute to future order flow.
→Overall, while exact order book figures are not stated, the optimistic sales guidance and inventory strategies suggest a strong pending order pipeline for H2 FY25 and beyond.

Capex plans

Yes

→Planned CapEx of around ₹80-90 crores funded through preferential allotment, focused on backward integration for technicals and intermediates.
→CapEx execution expected in multiple phases, with completion within 6 to 9 months (~2-3 quarters).
→The CapEx involves brownfield expansion, with plant trials and stabilization anticipated by Q1-Q2 FY26.
→Future growth planning for additional CapEx will be considered after current project completion.
→Development of a production facility for herbicides and patented formulations for international markets is in progress (timeline 1-3 years depending on registration).
→Strategic incorporation of a China subsidiary to boost collaborative R&D and enhance supplier cooperation.
→Overall investments aim at improving operational efficiency, expanding product portfolio, and strengthening market competitiveness worldwide.

How does Best Agrolife Ltd rank vs peers in Fertilizers & Agrochemicals?

Pro feature

1Best Agrolife Ltd

Rev 3Mar 1

See full Fertilizers & Agrochemicals sector rankings

Want more stocks like Best Agrolife Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio